Stockreport

AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis

AnaptysBio, Inc.  (ANAB) 
Last anaptysbio, inc. earnings: 3/2 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.anaptysbio.com/investor-relations
PDF 83 Percent of Patients Achieved EASI-50 at Day 29 Following a Single Dose of ANB020EASI-50 was Observed Early and Persisted Through Day 57Management to Host Conference C [Read more]